IL6 and pulmonary fibrosis: The influence of sIL-6R on Type 2 diabetes (OR: 1.298, 95% CI: 1.025-1.643; P=0.030), Parkinson’s disease (OR: 3.570, 95% CI: 1.653-7.709; P= 0.001), idiopathic pulmonary fibrosis (OR: 3.308, 95% CI: 1.178-9.292; P= 0.023), asthma (OR: 0.713, 95% CI: 0.548-0.927; P= 0.011), and asthmatic pneumonia(OR: 0.438, 95% CI: 0.277-0.693; P<0.001), suggests that IL-6 receptor blockade may modulate these five diseases by inhibiting the IL-6 trans-signaling pathway(Supplementary Material 1: Supplementary Table S5).